Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy
25 juin 2018 08h19 HE
|
Biomerica, Inc.
Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptomsApproximately 45 million Americans suffer from IBS1 Studies...
Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board
19 avr. 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today announced that it has added Harry L. Leider, MD, MBA to its Strategic Advisor Board, which is chaired by Edward...
Biomerica Announces Third Quarter Financial Results
17 avr. 2018 09h00 HE
|
Biomerica, Inc.
IRVINE, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the...
Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
08 mars 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced the Mexico’s COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios - Mexico’s equivalent...
Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter
16 janv. 2018 09h18 HE
|
Biomerica, Inc.
IRVINE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,613,636 for the three months ended November 30, 2017, compared to $1,432,206 for the...
China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
10 janv. 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced the China Food and Drug Administration (CFDA) approval of the EZ Detect™ colorectal screening test designed...
Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)
08 janv. 2018 08h19 HE
|
Biomerica, Inc.
- DGT Designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptoms - DGT can be used alongside current IBS drug treatments to potentially improve...
Biomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019
07 nov. 2017 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA) today announced that it has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea. Celtis...
Biomerica Reports 1st Quarter Fiscal 2018 Financials
17 oct. 2017 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,444,483 for the three months ending August 31, 2017, compared to $1,410,110 for the...
Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test
12 sept. 2017 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA) today announced that the Company has commenced clinical studies to evaluate the performance of its new and proprietary...